UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stall rare Cancer's spread
Disease control OngoingThis study compares the drug palbociclib alone versus palbociclib plus cemiplimab in 77 people with advanced dedifferentiated liposarcoma that cannot be removed by surgery. Palbociclib blocks enzymes that help cancer cells grow, while cemiplimab boosts the immune system to attack…
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy targets hard-to-treat liposarcoma
Disease control OngoingThis study tests whether combining two drugs—etrumadenant and zimberelimab—can shrink or slow advanced dedifferentiated liposarcoma that has returned, spread, or can't be removed by surgery. About 16 adults with this rare cancer will receive the treatment. The goal is to see how …
Matched conditions: UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC